611 related articles for article (PubMed ID: 23150707)
1. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
2. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
Gunderson LL; Moughan J; Ajani JA; Pedersen JE; Winter KA; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):638-45. PubMed ID: 24035327
[TBL] [Abstract][Full Text] [Related]
3. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.
Flam M; John M; Pajak TF; Petrelli N; Myerson R; Doggett S; Quivey J; Rotman M; Kerman H; Coia L; Murray K
J Clin Oncol; 1996 Sep; 14(9):2527-39. PubMed ID: 8823332
[TBL] [Abstract][Full Text] [Related]
4. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Ajani JA; Winter KA; Gunderson LL; Pedersen J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett C
JAMA; 2008 Apr; 299(16):1914-21. PubMed ID: 18430910
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08.
Konski A; Garcia M; John M; Krieg R; Pinover W; Myerson R; Willett C
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):114-8. PubMed ID: 18472363
[TBL] [Abstract][Full Text] [Related]
6. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014).
Matzinger O; Roelofsen F; Mineur L; Koswig S; Van Der Steen-Banasik EM; Van Houtte P; Haustermans K; Radosevic-Jelic L; Mueller RP; Maingon P; Collette L; Bosset JF;
Eur J Cancer; 2009 Nov; 45(16):2782-91. PubMed ID: 19643599
[TBL] [Abstract][Full Text] [Related]
7. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.
Ajani JA; Winter KA; Gunderson LL; Pedersen J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2009 Mar; 27(7):1116-21. PubMed ID: 19139424
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
[TBL] [Abstract][Full Text] [Related]
9. Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy?
Jiang Y; Mackley H; Cheng H; Ajani JA
J Natl Compr Canc Netw; 2010 Jan; 8(1):135-44. PubMed ID: 20064295
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
White EC; Goldman K; Aleshin A; Lien WW; Rao AR
Radiother Oncol; 2015 Nov; 117(2):240-5. PubMed ID: 26347494
[TBL] [Abstract][Full Text] [Related]
11. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.
Wo JY; Plastaras JP; Metz JM; Jiang W; Yeap BY; Drapek LC; Adams J; Baglini C; Ryan DP; Murphy JE; Parikh AR; Allen JN; Clark JW; Blaszkowsky LS; DeLaney TF; Ben-Josef E; Hong TS
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):90-95. PubMed ID: 31128146
[TBL] [Abstract][Full Text] [Related]
12. [Concurrent radiochemotherapy with 5-FU/mitomycin remains standard treatment for anal carcinoma. Long-term results of the phase III RTOG 98-11 trial].
Nieder C
Strahlenther Onkol; 2013 Jun; 189(6):512-3. PubMed ID: 23609134
[No Abstract] [Full Text] [Related]
13. Review of anal cancer patients at the Ottawa hospital.
Abunassar M; Reinders J; Jonker DJ; Asmis T
Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438
[TBL] [Abstract][Full Text] [Related]
14. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
Ben-Josef E; Moughan J; Ajani JA; Flam M; Gunderson L; Pollock J; Myerson R; Anne R; Rosenthal SA; Willett C
J Clin Oncol; 2010 Dec; 28(34):5061-6. PubMed ID: 20956625
[TBL] [Abstract][Full Text] [Related]
15. Management of anal cancer in 2010. Part 2: current treatment standards and future directions.
Abbas A; Yang G; Fakih M
Oncology (Williston Park); 2010 Apr; 24(5):417-24. PubMed ID: 20480740
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).
Meropol NJ; Niedzwiecki D; Shank B; Colacchio TA; Ellerton J; Valone F; Budinger S; Day JM; Hopkins J; Tepper J; Goldberg RM; Mayer RJ
J Clin Oncol; 2008 Jul; 26(19):3229-34. PubMed ID: 18490648
[TBL] [Abstract][Full Text] [Related]
17. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.
Glynne-Jones R; Kadalayil L; Meadows HM; Cunningham D; Samuel L; Geh JI; Lowdell C; James R; Beare S; Begum R; Ledermann JA; Sebag-Montefiore D;
Ann Oncol; 2014 Aug; 25(8):1616-22. PubMed ID: 24827136
[TBL] [Abstract][Full Text] [Related]
18. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients.
Doci R; Zucali R; La Monica G; Meroni E; Kenda R; Eboli M; Lozza L
J Clin Oncol; 1996 Dec; 14(12):3121-5. PubMed ID: 8955657
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I).
Glynne-Jones R; Sebag-Montefiore D; Adams R; Gollins S; Harrison M; Meadows HM; Jitlal M;
Cancer; 2013 Feb; 119(4):748-55. PubMed ID: 23011911
[TBL] [Abstract][Full Text] [Related]
20. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
